• Explore /
  • Poster
  • / NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.

NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.

Abstract Poster

Authors

null

Samuel A. Jacobs

NSABP Foundation, Inc., Pittsburgh, PA

Samuel A. Jacobs , Thomas J. George , Tatjana Kolevska , James Lloyd Wade III, Richard Zera , Gary L Buchschacher Jr., Tareq Al Baghdadi , Asheesh Shipstone , Daniel Lin , Greg Yothers , Katherine L. Pogue-Geile , Shannon Leigh Huggins-Puhalla , Carmen Joseph Allegra , Norman Wolmark

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Colorectal and Anal

Track

Gastrointestinal Cancer—Colorectal and Anal

Sub Track

Colorectal Cancer–Advanced Disease

Clinical Trial Registration Number

NCT03457896

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 3564)

DOI

10.1200/JCO.2022.40.16_suppl.3564

Abstract #

3564

Poster Bd #

358

Abstract Disclosures

Similar Posters

First Author: John H. Strickler

First Author: Yasushi Tsuji

First Author: Leena Gandhi

First Author: Samuel A. Jacobs